Recent News

• 03.04.2025 - Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
• 02.20.2025 - Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
• 02.11.2025 - Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
• 01.07.2025 - Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
• 01.06.2025 - Repligen Launches the CTech™ SoloVPE® PLUS System
• 01.06.2025 - Repligen Launches the CTech™ SoloVPE® PLUS System
• 12.12.2024 - Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
• 12.09.2024 - Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Recent Filings

• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - EX-99.1 EX-99.1
• 02.20.2025 - 8-K Current report